What is HUMA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HUMA?

P/E (TTM) is n/a and 52-week range is $0.39 to $1.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HUMA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HUMA?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-11.19B, EPS (TTM) near $-0.49 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Humacyte Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Durham, North Carolina, US, 269.6M shares outstanding, ISIN US44486Q1031 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Humacyte Inc

$HUMA

Health Care · Biotechnology

IR Run Scenarios

$0.41

-9.35%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 184 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The firm develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. The company is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The firm is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The firm is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Employees

184

Website

humacyte.com/

IPO

2020-09-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)